Evotec’s MytomAb platform represents a next‑generation approach to antibody innovation in oncology, designed to achieve unprecedented levels of target‑cell depletion. By harnessing the synergistic activity of NK and γδ T cells, MytomAb antibodies deliver significantly enhanced cytotoxic potency compared with conventional antibody engineering strategies. This unique format offers new therapeutic opportunities for partners seeking deeper, more durable responses in cancer treatment.
